摘要
慢病毒载体(LVs)是一种合适的用于调停肌肉萎缩症的基因治疗的候选载体,它们可感染分裂和非分裂细胞,并将其遗传物质整合到宿主基因组中,从而理论上可调节其长期表达。我们评价了LVs的能力是通过在五个不同的启动子的控制下的GFP报告基因,在体外转导和调停肌源性和非肌源性细胞的表达并在体内转导和调停骨骼肌纤维和干细胞(卫星细胞)的表达。我们进一步分析了在移植到营养不良,免疫缺陷的老鼠肌细胞中后,慢病毒载体转导的卫星细胞衍生的成肌细胞。脾病灶形成病毒启动子在所有的细胞类型中调停最高的基因表达;CBX3-HNRPA2B1染色质开放元件启动子在所有细胞中也具有活性,然而人类肌间线蛋白启动子在隔离或者与UCOE融合在一起时在非肌细胞中具有低的活性。令人意外的是人类骨骼肌肌动蛋白启动子在免疫细胞中也具有活性。人类肌间线蛋白启动子在体外调停强劲的,持久的肌原细胞中的报告基因表达,在体内调停卫星细胞和肌纤维细胞的报告基因的表达。人类肌间线蛋白启动子与UCOE结合不能明显的增加转基因表达。因此,我们的数据表明肌间线蛋白启动子适用于基因治疗。
关键词: 人类肌间线蛋白启动子,杜氏肌营养不良,慢病毒载体,成肌细胞,肌营养不良实验鼠,干细胞
Current Gene Therapy
Title:The Human Desmin Promoter Drives Robust Gene Expression for Skeletal Muscle Stem Cell-Mediated Gene Therapy
Volume: 14 Issue: 4
Author(s): Jacqueline Jonuschies, Michael Antoniou, Simon Waddington, Luisa Boldrin, Francesco Muntoni, Adrian Thrasher and Jennifer Morgan
Affiliation:
关键词: 人类肌间线蛋白启动子,杜氏肌营养不良,慢病毒载体,成肌细胞,肌营养不良实验鼠,干细胞
摘要: Lentiviral vectors (LVs) represent suitable candidates to mediate gene therapy for muscular dystrophies as they infect dividing and non-dividing cells and integrate their genetic material into the host genome, thereby theoretically mediating longterm expression. We evaluated the ability of LVs where a GFP reporter gene was under the control of five different promoters, to transduce and mediate expression in myogenic and non-myogenic cells in vitro and in skeletal muscle fibres and stem (satellite) cells in vivo. We further analysed lentivirally-transduced satellite cell-derived myoblasts following their transplantation into dystrophic, immunodeficient mouse muscles. The spleen focus-forming virus promoter mediated the highest gene expression in all cell types; the CBX3-HNRPA2B1 ubiquitously-acting chromatin opening element (UCOE) promoter was also active in all cells, whereas the human desmin promoter in isolation or fused with UCOE had lower activity in non-muscle cells. Surprisingly, the human skeletal muscle actin promoter was also active in immune cells. The human desmin promoter mediated robust, persistent reporter gene expression in myogenic cells in vitro, and satellite cells and muscle fibres in vivo. The human desmin promoter combined with UCOE did not significantly increase transgene expression. Therefore, our data indicate that the desmin promoter is suitable for the development of therapeutic purposes.
Export Options
About this article
Cite this article as:
Jonuschies Jacqueline, Antoniou Michael, Waddington Simon, Boldrin Luisa, Muntoni Francesco, Thrasher Adrian and Morgan Jennifer, The Human Desmin Promoter Drives Robust Gene Expression for Skeletal Muscle Stem Cell-Mediated Gene Therapy, Current Gene Therapy 2014; 14 (4) . https://dx.doi.org/10.2174/1566523214666140612154521
DOI https://dx.doi.org/10.2174/1566523214666140612154521 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hydroximic Acid Derivatives: Pleiotropic Hsp Co-Inducers Restoring Homeostasis and Robustness
Current Pharmaceutical Design Novel VEGF-independent Strategies Targeting Tumor Vasculature: Clinical Aspects
Current Pharmaceutical Design Patents on Immunotoxins and Chimeric Toxins for the Treatment of Cancer
Recent Patents on Drug Delivery & Formulation Receptor Tyrosine Kinases: The Main Targets for New Anticancer Therapy
Current Drug Targets IP6 & Inositol in Cancer Prevention and Therapy
Current Cancer Therapy Reviews Longevity Pathways: HSF1 and FoxO Pathways, a New Therapeutic Target to Prevent Age-Related Diseases
Current Aging Science The Delivery of Biologically Active (Therapeutic) Peptides and Proteins into Cells
Current Medicinal Chemistry Computer-Aided Drug Design Applied to Secondary Metabolites as Anticancer Agents
Current Topics in Medicinal Chemistry Daunorubicin Metabolism in Leukemic Cells Isolated from Patients with Acute Myeloid Leukemia
Drug Metabolism Letters Preservation of Cellular Glutathione Status and Mitochondrial Membrane Potential by N-Acetylcysteine and Insulin Sensitizers Prevent Carbonyl Stress-Induced Human Brain Endothelial Cell Apoptosis
Current Neurovascular Research Cornea: Window to Ocular Immunology
Current Immunology Reviews (Discontinued) Potential Therapeutic Applications of miRNA-Based Technology in Hematological Malignancies
Current Pharmaceutical Design Synthesis of 2-(Bis (2-Chloroethyl)Amino)-N-(5-Substitutedphenyl)- 1,3,4- Thiadiazol-2-Yl)Acetohydrazide And Evaluation of Anticancer Activity
Current Bioactive Compounds Molecular Pathways Linking Inflammation and Cancer
Current Molecular Medicine Targeting Oncogenes and Tumor Suppressors genes to Mitigate Chemoresistance
Current Cancer Drug Targets Towards an Ontology to Support Semantics Enabled Diagnostic Decision Support Systems
Current Bioinformatics Multi-Targeted Natural Products Evaluation Based on Biological Activity Prediction with PASS
Current Pharmaceutical Design Combining Angiogenesis Inhibitors with Radiation: Advances and Challenges in Cancer Treatment
Current Pharmaceutical Design Isoform Characterisation, Heterologous Expression and Functional Analysis of Two Lectins from Vatairea macrocarpa
Protein & Peptide Letters Melatonin as a Pleiotropic Molecule with Therapeutic Potential for Type 2 Diabetes and Cancer
Current Medicinal Chemistry